Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin Treatment by Nijmeijer, S. W. R. et al.
  
 University of Groningen
Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin
Treatment
Nijmeijer, S. W. R.; de Bruijn, E.; Verhagen, R.; Forbes, P. A.; Kamphuis, D. J.; Happee, R.;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Nijmeijer, S. W. R., de Bruijn, E., Verhagen, R., Forbes, P. A., Kamphuis, D. J., Happee, R., ... Koelman, J.
H. T. M. (2017). Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin
Treatment. Toxins, 9(9), [256]. https://doi.org/10.3390/toxins9090256
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Spectral EMG Changes in Cervical Dystonia Patients
and the Influence of Botulinum Toxin Treatment
S. W. R. Nijmeijer 1, E. de Bruijn 2, R. Verhagen 1, P. A. Forbes 2 ID , D. J. Kamphuis 3, R. Happee 2,
M. A. J. Tijssen 4,† and J. H. T. M. Koelman 1,†,*
1 Department of Neurology and Clinical Neurophysiology, Academic Medical Center, 1105 AZ Amsterdam,
The Netherlands; s.w.nijmeijer@amc.uva.nl (S.W.R.N.); r.verhagen@amc.uva.nl (R.V.)
2 BioMechanical Engineering, Delft University of Technology, 2628 CD Delft, The Netherlands;
edodebruijn@gmail.com (E.d.B.); p.a.forbes@tudelft.nl (P.A.F.); r.happee@tudelft.nl (R.H.)
3 Department of Neurology, Reinier de Graaf Groep, 2625 AD Delft, The Netherlands;
Daan.Kamphuis@rdgg.nl
4 Department of Neurology AB 51, University of Groningen, 9713 GZ Groningen, The Netherlands;
m.a.j.de.koning-tijssen@umcg.nl
* Correspondence: J.H.Koelman@amc.uva.nl; Tel.: +31-020-5669-111
† These authors contributed to this work equally.
Academic Editors: Jennifer G. Goldman and Codrin Lungu
Received: 4 July 2017; Accepted: 14 August 2017; Published: 23 August 2017
Abstract: Botulinum toxin (BoNT) injections in the dystonic muscles is the preferred treatment for
Cervical Dystonia (CD), but the proper identification of the dystonic muscles remains a challenge.
Previous studies showed decreased 8–14 Hz autospectral power in the electromyography (EMG)
of splenius muscles in CD patients. Cumulative distribution functions (CDF’s) of dystonic muscles
showed increased CDF10 values, representing increased autospectral powers between 3 and 10 Hz,
relative to power between 3 and 32 Hz. In this study, we evaluated both methods and investigated
the effects of botulinum toxin. Intramuscular EMG recordings were obtained from the splenius,
semispinalis, and sternocleidomastoid muscles during standardized isometric tasks in 4 BoNT-naïve
CD patients, 12 BoNT-treated patients, and 8 healthy controls. BoNT-treated patients were measured
4–7 weeks after their last BoNT injections and again after 11–15 weeks. We found significantly
decreased 8–14 Hz autospectral power in splenius muscles, but not in the semispinalis and
sternocleidomastoid muscles of CD patients when compared to healthy controls. CDF10 analysis
was superior in demonstrating subtle autospectral changes, and showed increased CDF10 values in
all studied muscles of CD patients. These results did not change significantly after BoNT injections.
Further studies are needed to investigate the origin of these autospectral changes in dystonia patients,
and to assess their potential in muscle selection for BoNT treatment.
Keywords: cervical dystonia; botulinum toxin; EMG; autospectral analysis; muscle selection
1. Introduction
Dystonia is a syndrome characterized by sustained or intermittent involuntary muscle
contractions, leading to debilitating abnormal postures and twisting movements [1]. In cervical
dystonia (CD), the most common form of primary dystonia, the neck muscles are primarily involved [2].
The first line treatment for CD is botulinum toxin (BoNT) injection in the dystonic muscles [3]. For an
optimal treatment effect, proper selection of the dystonic muscles is essential [4,5]. Unfortunately, no
specific tools are available to reliably identify dystonic muscles, and discriminate them from healthy
compensating muscles [6]. In a previous study we obtained intramuscular electromyography (EMG)
recordings to investigate the autospectra of the EMG envelope and intermuscular coherences as
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possible discriminative tools to identify dystonic muscles [7]. The most discriminating finding was
an 8–14 Hz autospectral peak that was measured in the splenius capitis (SPL) muscles of almost all
healthy controls during isometric contraction, but that was absent in the majority of the dystonic SPL
muscles in patients. In a subsequent study we developed an isometric setup so that EMG recordings
could be obtained during standardized, reproducible isometric tasks [8]. In analyzing the collected
data we developed a new analysis method, capable of demonstrating more subtle autospectral changes
in dystonic muscles. Cumulative distribution functions (CDF) provides a measure for the relative
distribution of autospectral power. In this study, CDF was used to demonstrate an increase in power
between 3 and 10 Hz (CDF10 value) relative to the power between 10 and 30 Hz in dystonia patients [9].
Higher CDF10 values were found on a group level in the SPL, the sternocleidomastoid (SCM), and the
semispinalis capitis (SESP) muscles of CD patients when compared to equivalent muscles in healthy
controls. This represents a power shift towards the lower frequency band (3–10 Hz) in these muscles.
This pilot study, however, had several important limitations that we aim to address in the current
study. An important limitation was that surface EMG electrodes were used, and electric crosstalk
between the anatomically closely related neck muscles might have impaired the accurate identification
of individual dystonic muscles. Another important limitation in all of the above-described studies
was that all patients had already been treated with BoNT injections. BoNT injections cause muscle
atrophy, decrease the EMG amplitude [10], influence muscle fiber velocity [11], and might reduce the
median frequency of EMG autospectra [12]. All patients were measured at least 3 months after their
previous BoNT treatment, but BoNT might still have had some effect after that period [12]. The precise
effects of BoNT on the above-described autospectral changes are unknown, and therefore the influence
of previous BoNT treatments on these results cannot be excluded. In the current study, we obtained
intramuscular EMG recordings during standardized isometric tasks. Autospectra and CDF’s were
evaluated in 4 BoNT-naïve patients, 12 BoNT-treated patients, and 8 healthy controls. All BoNT-treated
patients were measured twice. The first measurement was 4–7 weeks after their last BoNT injections,
and the second measurement was after 11–15 weeks, when most clinical BoNT effects are expected
to have worn off [13]. The first goal was to investigate 8–14 Hz autospectral peaks and CDF10 values
in our improved setup in CD patients and controls. The second goal was to investigate the possible
confounding effect of BoNT on these results.
2. Results
2.1. Study Population
Twelve BoNT-treated patients (5 males and 7 females) aged between 46 and 74 years
(mean age ± SD, 63 ± 8.9 years), and 4 BoNT-naïve patients (1 male and 3 females) aged between
44 and 63 years (mean age ± SD, 55 ± 8.0 years) participated in this study. In addition, 8 healthy
controls aged between 41 and 65 years (mean age ± SD, 51.5 ± 9.9 years) were recruited. For patients,
the duration of their symptoms ranged from 3 to more than 40 years in the BoNT-treated patients
(median; IQR, 8.5 years; 4.0–20.0 years), and from 2 to 20 years in BoNT-naïve patients (median; IQR,
10.5 years; 2.75–19.0 years). In the BoNT-treated patients, the mean TWSTR score was 29.6 (SD: 11.24).
In BoNT-naïve patients the mean TWSTR score was 31.25 (SD: 13.25). For the BoNT-treated patients, the
first measurement ranged from 29 to 45 days (median; IQR, 32 days; 30–37.5 days) after the previous
BoNT treatment, and the second measurement ranged from 80 to 105 days (median; IQR, 96 days;
91–99 days) after the previous BoNT treatment. Clinical characteristics of the individual patients are
presented in Table 1. All BoNT-treated patients received BoNT injections according to their usual
treatment scheme tailored by their treating neurologist before participating in this study. Patient 07
received onabotulinumtoxinA (Botox®) injections, and all other BoNT-treated patients were treated
with abobotulinumtoxinA (Dysport®) injections.
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Table 1. Clinical characteristics. Pat. nr.: patient number. Patients 1–12 are the botulinum toxin (BoNT)-treated patients and patients 21–24 are the BoNT-naïve patients.
1 M: male F: female. 2 R: right; L: Left; 3 Numbers 1 to 3 indicate the degree of rotation, laterflexion, antecollis or retrocollis: 1: 0–15 degrees; 2: 15–30 degrees; 3:
>30 degrees. 4 A: antecollis; R: retrocollis; NP: no antecollis or retrocollis present. 5 0: no visible tremor 1: mild or intermittent tremor 2: pronounced tremor. 6 Total
dosage of BoNT-injections during the previous treatment; MU: mouse units. N.A.: not applicable; B: onabotulinumtoxinA (Botox®) D: abobotulinumtoxinA (Dysport®).






and Type 6Rotation 2,3 Lateroflexion 2,3 Antecollis/Retrocollis 3,4
01 F 51 L3 L2 NP 0 57.5 4 320 (D)
02 F 72 L1 R1 A1 1 36.75 36 190 (D)
03 M 67 L2 R1 NP 2 21 14 810 (D)
04 F 74 R2 R1 NP 1 14 4 240 (D)
05 F 65 R3 R1 NP 0 37.5 4 220 (D)
06 M 53 L2 R1 NP 1 20 20 410 (D)
07 F 61 R1 R1 NP 1 23.5 13 150 (B)
08 M 64 L2 L1 NP 0 26 >40 540 (D)
09 F 46 R1 R1 NP 1 35 4 240 (D)
10 F 66 L2 R1 A2 1 27 20 350 (D)
11 M 73 L2 R1 NP 1 29 3 640 (D)
12 M 64 R3 R1 A2 2 28 21 350 (D)
21 M 57 L1 L1 A1 1 33 2 N.A.
22 F 44 L1 R1 R1 1 16 20 N.A.
23 F 63 L3 R3 R3 2 48 16 N.A.
24 F 56 L1 L1 NP 1 28 5 N.A.
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2.2. Maximal Force and Torque during Maximal Voluntary Muscle Contractions (MVC) Tasks
The means of the maximal horizontal rearward force, and maximal left and right rotational torque
produced by patients and controls during the MVC tasks are shown in Table 2. The maximal delivered
forces and torques were on average higher in healthy controls when compared to patients, although
these differences were not statistically significant.
Table 2. Maximal force and torque. N: Newton; Nm: Newton Metre; SD: standard deviation; ns: not
statistically significant compared to healthy controls.





Healthy controls 129.18 N (SD: 62.43) 6.25 Nm (SD: 3.40) 6.59 Nm (SD: 3.7)
BoNT-treated patients
First measurement 93.36 N (SD: 36.24, ns) 4.04 Nm (SD: 2.40, ns) 4.66 Nm (SD: 2.49, ns)
BoNT-treated patients
Second measurement 102.63 N (SD: 34.55, ns) 5.168 Nm (SD: 2.42, ns) 5.03 Nm (SD: 2.65, ns)
BoNT-naïve patients 88.10 N (SD: 28.52, ns) 4.92 Nn (SD: 1.77, ns) 4.86 Nm (SD: 2.34, ns)
2.3. Task Performance
In healthy controls, on average 4.9 of the 6 trials were completed successfully. In the BoNT-treated
patients, on average 2.9 of the 6 trials were completed successfully during the first measurement,
and 3.4 of the 6 trials were completed successfully during the second measurement. The BoNT-naïve
patients completed 3.3 of the 6 trials successfully.
2.4. Raw EMG Inspection
In most CD patients, the amplitude of the EMG signals was generally lower when compared
to healthy controls, possibly reflecting a lower level of muscle contraction (see discussion). Nine
EMG recordings from individual muscles during one of the measurements were excluded because of
artefacts or needle displacements. In two patients (numbers 7 and 10), large artefacts were observed
in the EMG of multiple muscles during several trials. As a result, the complete first measurement
of patient number 10 had to be excluded from further analysis. For patient number 7, the second
repetition of each trial from the first measurement had to be excluded.
2.5. EMG Spectral Analysis: Pooled Autospectra
In Figure 1, the pooled autospectra of the rectified EMG are displayed per group by the average
of the log-transformed autospectra, including the 95% confidence intervals. In healthy controls, a clear
8–14 Hz peak is seen in the SPL muscles, and a more subtle 8–14 Hz peak is seen in the SESP muscles.
This peak was absent in the SCM muscles. In the BoNT-treated muscles, no 8–14 Hz peaks were
seen in any of the muscles. In the BoNT-naïve patients, a subtle 8–14 Hz peak was seen only in the
SESP muscles.
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Figure 1. Pooled autospectra of the rectified electromyography (EMG) between 3 and 30 Hz. Solid
line: mean of the log-transformed autospectra. Dotted line: 95% confidence intervals. In BoNT-treated
patients the autospectra from the second measurements are shown, when most BoNT effects are
expected to have worn off. Similar autospectra were seen during the first measurement.
2.6. EMG Spectral Analysis: 8–14 Hz Area Under the Curve (AUC’s) in SPL Muscles
The 8–14 Hz AUC’s are shown in Table 3. The 8–14 Hz AUC was significantly lower in the
ipsilateral (presumed dystonic) SPL muscles in BoNT-treated patients when compared to the SPL
muscles of healthy controls, both during the first and during the second measurement. In the
contralateral (non-dystonic) SPL muscles, the AUC was also lower when compared to the healthy
controls, but the difference was only statistically significant during the first measurement (4–7 weeks
after BoNT treatment). For the four BoNT-naïve patients, the 8–14 Hz AUC was lower only in the
ipsilateral SPL muscles, but this difference was not statistically significant.
2.7. EMG Spectral Analysis: 8–14 Hz AUC’s in SCM and SESP Muscles
A tr nd was observed towards l wer 8–14 Hz AUC’s in the contralater l (presumed dystonic)
SCM muscles of BoNT treated patients when c mpared to healthy controls. This difference was only
statistically significant during the first measurement. There were no significant differences in the
8–14 Hz AUC’s in the SESP muscles between patients and controls.
2.8. Effect of BoNT Treatment on the 8–14 Hz AUC’s
Only in the contralateral (non-dystonic) SPL muscles, a statistically significant difference was
observed between the first and the second measurement: the 8–14 Hz AUC was lower during the first
measurement (p < 0.05). In the other muscles, no statistically significant differences were observed
between the AUC’s from the first and second measurement. Figure 2 shows an example of the pooled
autospectra of the ipsilateral SPL muscle in BoNT-treated patients during the first and during the
second measurement.
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Table 3. 8–14 Hz area under the curve (AUC’s) of the log-transformed autospectra. IQR: interquartile
range. N = number of subjects used for analysis. * p values indicate the level of statistical significance of
the difference in 8–14 Hz AUC’s compared to the corresponding muscles in healthy controls. Ns = not
statistically significant. Results highlighted in bold represent statistically significant values. First
measurement: 4–7 weeks after the previous BoNT treatment. Second measurement: 11–15 weeks after
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2.9. Effect of Age, Gender and Tremor
There was no statistically significant correlation between age and the mean 8–14 Hz AUC’s.
Furthermore, there was no significant difference in 8–14 Hz AUC’s between men or women.
To evaluate the effect of tremor on the observed 8–14 Hz autospectral changes in the ipsilateral
SPL muscles, we compared the 8–14 Hz AUC’s of the ipsilateral SPL muscles in patients with (N = 9),
and without tremor (N = 3). The median 8–14 Hz AUC’s were comparable in patients with tremor
(first measurement: 4.25; second measurement: 5.09) and patients without tremor (first measurement:
4.84; second measurement: 3.75). These differences were not statically significant.
2.10. CDF10 Analysis
The CDF10’s are shown in Table 4. The median CDF10 was higher in all of the muscles in
patients when compared to the corresponding muscles in healthy controls. In the SPL muscles, the
differences were statistically significant in both the ipsilateral and the contralateral SPL muscles in
the BoNT-treated and the BoNT naïve patients. In the SCM muscles, the differences were statistically
significant in the contralateral (dystonic) SCM muscles of the BoNT-treated patients and BoNT-naïve
patients and in the ipsilateral (non-dystonic) SCM muscles only during the second measurement in
the BTX-treated patients. In the SESP muscles, the differences were statistically significant in the
BoNT-treated patients, but not in the BoNT-naïve patients. Plots of the CDF’s of the ipsilateral SPL
muscles in patients, and the SPL muscles in healthy controls are shown in Figure 3.
Table 4. CDF10 values. CDF10: (Cumulative Distribution Function) at 10.13 Hz. IQR: interquartile
range. N = number of subjects used for analysis. * p values indicating the level of statistical
significance of the difference in CDF10 values compared to the corresponding muscles in healthy
controls. Ns = notstatistically significant. Results highlighted in bold represent statistically significant
values. First measurement: 4–7 weeks after the previous BoNT treatment. Second measurement:
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(N = 3). However, after excluding all patients with t emor, the CDF10 valu s were still significantly
hig r in th ipsilateral SPL (p < 0.05), nd contralateral SCM (p < 0.05) muscles the remaining
patients (N = 3) compared to healthy contr ls during both measurements.
2.13. iagnostic Potential to iscri inate ystonia Patients fro ealthy Controls
2.13.1. 8–14 Hz AUC’s
A receiver operating characteristic (ROC) curve was made using the 8–14 Hz AUC’s of all
individual muscles of patients and controls. No cut-off existed with an acceptable sensitivity and
specificity to discriminate patients from healthy controls, the area under the curve was 0.353.
2.13.2. CDF10’s
A ROC curve was made using the CDF10 values of all individual muscles of patients and controls.
The area under the curve was 0.887. With a cut-off of 0.222, the sensitivity of CDF10 to identify patients
was 0.773, and the specificity was 0.870 (Figure 4). In only one of the 8 healthy controls, and in 11 of
the 12 BoNT-treated patients, at least half of the muscles had a CDF10 above 0.222 (Figure 5).
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Figure 5. Number of muscles with a CDF10 above 0.222. Figure 5 illustrates the number of subjects
(CD patients in red and healthy controls in blue) that have a certain number of muscles (specified on
the x-axis) with CDF10 values above 0.222.
3. Discussion
In this study, intramuscular EMG recordings were obtained during standardized isometric tasks
to investigate 8–14 Hz autospectral changes, and CDF10 values in CD patients when compared to
healthy controls. We found significant autospectral changes in CD patients that were more evident
when CDF10 analysis was used. The autospectral changes could not be explained by the effect of
BoNT injections.
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3.1. 8–14 Hz Autospectral Peaks in Healthy Controls
In line with previous studies [7,14], we found 8–14 Hz autospectral peaks in the SPL muscles of
healthy controls, but not in CD patients. Several studies [7,14,15] have found evidence for synchronized
activity at around 10–15 Hz in healthy neck muscles. These oscillations are hypothesized to facilitate
common muscle synergies, and may originate from the reticular formation [15,16]. In limb muscles,
oscillations are found in a higher (15–35 Hz) frequency band, and are linked to a corticospinal drive [17].
Blouin et al. therefore proposed that voluntary cortical activation of the neck motor neurons occurs
through a relay in the reticular formation instead of a direct corticospinal projection [15]. In line
with previous studies [7,14] we were unable to observe the same 8–14 Hz peaks in the autospectra
of SCM muscles, and they were less evident in SESP muscles. It is possible that during our specific
isometric experiments, the SPL muscles but not the SCM muscles were recruited into muscle synergies
facilitated by 8–14 Hz oscillations. It could be speculated that the SCM and the SESP muscles would
show similar 8–14 Hz autospectral peaks in slightly different postures, or when forces are produced
in other directions. Another explanation might be that the absence of 8–14 Hz autospectral power in
SCM muscles reflects differences in the innervation between cranial nerves (SCM) and spinal nerves
(SPL and SESP).
3.2. Absence of 8–14 Hz Autospectral Peaks in Dystonia Patients
In dystonia patients, the 8–14 Hz autospectral peaks were absent in the SPL muscles during
isometric tasks. If the hypothesis that these peaks reflect oscillations originating from the reticular
formation is correct, their disappearance might point towards the involvement of the reticulospinal
pathway in the pathophysiology of dystonia. Alternatively, in dystonia patients, there might be
differences in muscle synergies resulting from longstanding changes in posture. Similarly, it is possible
that slightly different posturing of the neck in patients during the experiments influenced the use of
muscle synergies. In addition, suboptimal task performance in patients might have resulted in different
patterns of muscle recruitment. It can, however, not be excluded that the observed autospectral
differences are the result of other factors like muscle atrophy caused by multiple BoNT injections,
or the generally lower degrees of muscle contraction in patients (see limitations). Finally, we have
considered the explanation that normal 8–14 Hz autospectral peaks are masked or suppressed by a
more prominent dystonic drive in the 4–7 Hz frequency band, as previously described in dystonia
patients [7,14,18]. However, this seems unlikely as no clear 4–7 Hz peaks were seen in the pooled
autospectra of patients.
3.3. CDF10 Analysis
CDF10 values were higher in all muscles in CD patients when compared to healthy controls,
reflecting an increase in power between 3 and 10 Hz, relative to the power between 10 and 32 Hz.
The higher CDF10 in patients could be explained by an increase in power of between 3 and 10 Hz,
or by a decrease in power between 10 and 32 Hz. In this study we have found a decrease of
8–14 Hz autospectral power in patients when compared to the healthy controls. Because the 8–14 Hz
autospectral peaks in the healthy controls were predominantly caused by power above 10 Hz
(see Figure 1), the disappearance of these peaks in patients contributed to higher CDF10 values
in patients. It is however unlikely that 8–14 Hz peaks are the only explanation for the higher CDF10
values because, unlike the higher CDF10 values, 8–14 Hz autospectral differences were not found in all
muscles. An additional explanation might be increased activity in the 3–10 Hz band. EMG activity
around 4–7 Hz has frequently been described in dystonia patients reflecting a dystonic drive, probably
originating from the basal ganglia [7,14,19]. This drive is mostly seen in patients with rhythmic EMG
activity, or even a visible dystonic tremor [7]. In this study, CDF10 values were indeed higher in
most muscles in patients with tremor. However, it is unlikely that the 4–7 Hz dystonic drive, or a
dystonic tremor are the only explanations for the higher CDF10 values as no clear 4–7 Hz peaks were
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visible in the pooled autospectra (Figure 1) that would explain the higher CDF10 values. Furthermore,
significantly higher CDF10 values were also observed in patients without tremor. In conclusion, the
higher CDF10 values in CD patients are probably the result of a combination of elevated power in
the 4–7 Hz band, and reduced power in the 8–14 Hz band. Compared to autospectral analysis, CDF
analysis is a more sensitive method to find subtle shifts in autospectral power in CD patients.
3.4. Effect of BoNT
To investigate the effect of BoNT on the 8–14 Hz autospectral changes and the higher CDF10 values,
we measured the BoNT-treated patients twice. The first measurement was after 4–7 weeks, and the
second measurement was 11–15 weeks after their previous BoNT treatment, when most BoNT effects
are expected to have worn off [13]. Only in the contralateral (presumed non-dystonic) SPL muscles
there was a statistically significant difference in 8–14 Hz autospectral power between the first and
the second measurements. No statistically significant differences were observed in the other muscles,
including the ipsilateral SPL muscles, where 8–14 HZ autospectral differences between patients and
controls were the most evident. In the BoNT-naïve patients, no statistically significant differences in
8–14 Hz power were observed when compared to healthy controls. However, no definite conclusions
can be drawn from this small group of BoNT-naïve patients (N = 4). For CDF10 values, no statistically
significant differences were observed between the first and the second measurement. There was even
a trend towards slightly higher CDF10 values during the second measurements. Furthermore, even
in this small group of BoNT-naïve CD patients, significantly higher CDF10 values were observed
when compared to healthy controls in the contralateral (presumed dystonic) SCM muscles and in the
bilateral SPL muscles. Taken together: although we acknowledge that residual effects of BoNT can
certainly not be ruled out, it seems unlikely that the observed low frequency autospectral differences
are a pure BoNT effect. Therefore, it would be interesting to reproduce our findings in a larger group
of BoNT naïve patients.
3.5. Task Performance
As could be expected, the number of successfully completed trials was higher in healthy controls.
This confirms that dystonia patients have more difficulty in generating certain specific submaximal
isometric forces. This could be the result of abnormal muscle activation patterns in dystonia patients
during isometric tasks, as previously described [8]. Interestingly, in BoNT treated patients, the number
of successfully completed trials was higher during the second measurement when effects of BoNT are
expected to have worn off. This might be a training effect as patients were already familiar with the
isometric tasks during the second measurement.
3.6. Limitations
The most important limitation of this study was the small group of BoNT-naïve patients measured,
as discussed above. An additional limitation might be the EMG artefacts that were observed in
many subjects. These artefacts were caused by fluctuations in the currents exceeding the range
of the EMG amplifier. Artefacts predominantly occurred when patients moved around between
trials and were absent or limited in most of the relevant EMG segments. We excluded the trials
with apparent artefacts in the relevant EMG segments. Finally, upon inspection of the raw EMG
data, we noticed that the amplitude was generally higher in most muscles in the healthy controls.
A higher amplitude is a measure of the magnitude of muscle force, suggesting a lower degree of
muscle activation in patients [20]. Possibly, patients had more difficulty activating the correct muscles
needed for specific tasks. Indeed, task performance was inferior in patients when compared to healthy
controls. In addition, healthy controls might have had a higher overall degree of muscle contraction.
This was reflected by higher produced maximal forces and torques by healthy controls, although these
differences were not statistically significant. Another explanation for the lower EMG amplitude in
patients might be the muscle atrophy caused by repeated BoNT treatment in patients. Finally, a lower
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amplitude in CD patients might have also have been caused by other factors, such as suboptimal needle
placement, further away from the motor units [21]. The influence of these factors on the autospectral
results is unclear, but to minimize the influence of differences in the autospectral power on our results,
all autospectra were normalized before spectral analysis.
3.7. Future Perspectives and Potential Clinical Applications
CDF10 analysis is superior in demonstrating subtle low frequency autospectral changes in CD
patients. Based on CDF10 values, we were able to discriminate patients from healthy controls with a
sensitivity of 77%, and a specificity of 87%. Further studies are needed to investigate how adequate
these tools are for the identification of dystonic muscles within patients. To determine the value
of these autospectral changes for muscle selection before BoNT treatment, a large trial should be
performed towards the effect of these methods on the outcome of BoNT treatment. Our results suggest
that these autospectral changes do not change significantly after BoNT injections. If these methods can
indeed also be applied in patients already treated with BoNT, it becomes more feasible to perform such
a trial. Finally, frequency analysis of EMG recordings during different physiological and pathological
conditions might provide more insight in the role of oscillatory drives towards neck muscles in healthy
subjects and in dystonia.
4. Conclusions
In line with previous studies, we confirm the finding of 8–14 Hz autospectral peaks in the SPL
muscles of healthy controls that are absent in dystonic SPL muscles in CD patients. Furthermore, we
have shown that more subtle low frequency autospectral changes can be found in more muscles with
CDF analysis, and that this method is superior in discriminating healthy controls from dystonia patients.
Further studies are needed to investigate the origin of these autospectral changes, to determine how
adequate these tools are for muscle selection for BoNT treatment, and to confirm that these methods
can also be applied after patients have received BoNT.
5. Materials and Methods
5.1. Study Population
Patients were recruited from a population of patients with CD, treated at the botulinum toxin
outpatient clinic of the Academic Medical Center in Amsterdam (AMC). In addition, all neurologists
connected to “DystonieNet” (a Dutch collaboration of neurologists specialized in dystonia, website:
www.dystonienet.nl) were asked to inform eligible patients and ask them to participate in our study.
Inclusion criteria were: (1) patients with idiopathic CD, and (2) a rotational component in the dystonic
posturing. Exclusion criteria were: (1) fixed dystonia, or (2) secondary dystonia. Both BoNT-naïve
patients, and those that were already receiving BoNT injections (BoNT-treated patients) were included.
The BoNT-treated patients were measured twice: the first measurement was always between 4 and
7 weeks after the previous BoNT treatment, and the second measurement was always between 11 and
15 weeks after the previous treatment. Healthy controls were recruited using information posters in
the AMC, and by asking the partners of patients. All subjects gave written, informed consent, and
the study was approved by the medical ethics committee of the AMC (project code: 2013-134, date of
approval: august 26TH, 2013).
5.2. Clinical Examination
All subjects underwent a systematic neurological examination. For patients, dystonic symptoms
were scored during their second visit using the Toronto Western Spasmodic Torticollis Rating Scale
(TWSTRS, range: 0–87) [22].
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5.3. Apparatus
Subjects were seated and fixed in an isometric device (Figure 6), with a tightly fitted cushioned
helmet. They performed isometric neck muscle contraction tasks to generate horizontal force and
rotational torque (spinal axis) that were measured by an overhead six axis load cell (MC3-6-500, AMTI
Inc., Watertown, MA, USA). Force and torque signals were sampled at 2048 Hz. Subjects received
visual feedback of the generated force and torque on a monitor in front of them. Visual feedback was
presented through a custom made interface using Motek software (Motek Medical BV, Amsterdam,
The Netherlands). After each task, a trigger pulse was sent to the EMG amplifier to mark the beginning
and end of each trial in the EMG recordings.
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Figure 6. The isometric contraction device. The square represents a helmet on the subject’s head that is
attached to the force/torque sensor.
5.4. EMG Recordings
EMG was recorded and monitored using Micromed Systemplus Evolution (Mogliano Veneto,
Treviso, Italy). Signals were amplified using a Micromed amplifier (SAM32RFO FC 32 channel
headbox). Intramuscular EMG recordings were obtained bilaterally from the SCM, SPL, and SESP
muscles using concentric needle electrodes. The needle electrodes were inserted by an experienced
clinical neurophysiologist or by one of the investigators (S.N.) under supervision of an experienced
clinical neurophysiologist. The wires of the electrodes were secured to the subject, using tape to
prevent the needles from moving. Signals were sampled at 2048 Hz and monitored continuously
during the experiment. If the signal was lost or the EMG activity was no longer visible during muscle
contraction, the electrodes were checked and needles were re-inserted as necessary.
5.5. Isometric Contraction Experiments
ll tasks ere explained to the subjects before the start of the experi ent. nce secured in the
iso etric setup, subjects performed several practice runs to familiarize themselves with the device and
the nature of the visual feedback. The experiment consisted of maximal and submaximal voluntary
isometric contractions. First, subjects performed maximal voluntary muscle contractions (MVC) using
neck muscles to generate head forces in one horizontal direction (rearward), and to generate left and
right rotational torque. These MVC trials lasted five seconds in each direction, and were repeated
t ice. After the MVC trials, EMG needle electrodes were inserted bilaterally in the SPL, SCM, and
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SESP muscles for the subMVC trials. Patients now aimed to generate 20% of their MVC in the above
mentioned directions. To reduce differences in task-performance between subjects, positive visual
feedback was given when patients produced the target force/torque with a maximum error of 35%,
and no concurrent force or torque greater than 35% of the target force/torque in any other direction.
For example, if patients involuntarily produced a concurrent force greater than 35% of the target
force in the horizontal plane during a rotation task, no positive feedback was given. After the target
force/torque was reached, a timer started counting down from 8 s. In order to successfully complete
the trial, subjects had to produce a stable force/torque, and remain within the prescribed limits for the
full 8 s. All subjects were given several attempts of 30 s to successfully complete these trials. If the
subjects were unable to complete a trial, they were instructed to maintain a steady force/torque as
close as possible to the target force/torque for at least 8 s without making any further compensating
movements. The sub-MVC trials were repeated at least twice in all directions. If no two successfully
completed trials were available, the EMG recordings obtained during their two best attempts were
used for further analysis.
5.6. Selection of Tasks and Muscles for Spectral Analysis
All muscles were analyzed during the task in which they were most likely to be active. The right
SPL and left SCM were analyzed from the right rotational torque tasks and the left SPL, and the
right SCM from the left rotational torque tasks. The SESP muscles were analyzed from the tasks in
which subjects produced a horizontal rearward force. In patients, a distinction was made between
the SCM and SPL muscles ipsilateral, and the SCM and SPL muscles contralateral to the direction
of their dystonic posturing. The ipsilateral SPL and the contralateral SCM were most likely to be
responsible for the rotational component of the dystonia (presumed dystonic muscles), and were
therefore expected to show the most abnormalities specific for dystonia.
5.7. EMG Visual Inspection
All raw EMG recordings were visually inspected and checked for reliable EMG activity and for
unwanted artefacts. If no EMG activity was visible during muscle contraction, or if many artefacts
were observed, the corresponding trials were excluded from further analysis. In most subjects, artefacts
were observed in a limited number of EMG recordings. These were most likely caused by fluctuations
in the EMG voltage exceeding the range of the EMG amplifier. These artefacts mainly occurred
when subjects were moving in between tasks. If such artefacts were observed during the experiment,
the corresponding trial was repeated. If significant artefacts were noticed after the experiment, the
corresponding trial was excluded from further analysis.
5.8. EMG Pre-Processing
EMG signals were processed offline using Vision Analyser 2.0 (Brain Products GmbH, Gilching,
Germany). The raw bipolar EMG was notch filtered at 50 Hz, high pass filtered at 20 Hz (4th order
zero-phase), low pass filtered at 750 Hz, and full wave rectified to obtain the EMG envelope. The last
0.5 s of each task were discarded because in many subjects the trigger pulse indicating the end of
a trial created artefacts in the EMG data. Therefore, in each direction, two segments of 7.5 s were
used for further analysis. To reduce the effects of variability in EMG amplitude between patients,
each rectified EMG recording was normalized using the median of the amplitudes of the entire 7.5 s
recording. The median was chosen here to minimize the influence of high amplitude discharges in
the EMG.
5.9. EMG Spectral Analysis
Low frequency characteristics of the EMG envelope were studied offline using Matlab (Matworks
Inc., Natick, Massachusetts, USA) by calculating the autospectrum of the normalized rectified EMG
recordings. For each 7.5 s trial, the autospectrum was calculated by averaging the discrete Fourier
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transformations of four non-overlapping 1.875 s segments, resulting in a frequency resolution of
0.5333 Hz. If two trials for one task were available, the autospectra were averaged over these
trials. For group comparison, pooled autospectra were calculated using an average of the individual
autospectra. Two measures were obtained from the individual autospectra using both of the absolute
low-frequency powers and the CDF’s. Because the absolute low-frequency powers of the EMG
envelope were skewed to the right, the autospectra were log-transformed. Subsequently, the
power between 8 and 14 Hz was investigated by calculating the area under the curve (AUC) of
the log-transformed autospectrum between 8 Hz and 14 Hz (more precisely 13.87 Hz because of
frequency resolution restrictions). A second measure was obtained from the normalized CDF which
was calculated to demonstrate the more subtle differences in the lower (3.2–32 Hz) frequency band [9].
The CDF was normalized to be zero at 3.2 Hz and one at 32 Hz, such that the CDF at 10 Hz (more
precisely 10.13 Hz because of frequency resolution restrictions—from here on called CDF10) signified
the power present in the lower (3.2–10 Hz) band as a ratio of the power over the full frequency band
(3.2–32 Hz) band.
5.10. Potential of 8–14 Hz AUC’s and CDF10 to Discriminate Dystonia Patients from Healthy Controls
To investigate the potential of 8–14 Hz AUC’s and CDF10 values to discriminate dystonia patients
from healthy controls, ROC (receiver operating characteristic) curves were calculated using the ROC
function in SPSS. The 8–14 Hz AUC’s and CDF10 values of all individual muscles were used as the
test variable and the subject to which they belonged (patient or healthy control) was used as the state
variable. The resulting ROC curves show the sensitivity and specificity for different CDF10 values, and
8–14 Hz AUC’s (represented by the different points on the curve) to discriminate CD patients from
healthy controls. Based on this ROC curve, an optimal cut-off value was identified (value with the
highest sensitivity and specificity) and subsequently the number of muscles above that cut-off value
was compared between patients and controls.
5.11. Statistical Analysis
Clinical characteristics are presented using the mean and standard deviation (SD) for normally
distributed data, and median and interquartile range (IQR) for non-normally distributed data. Due to
the small numbers of patients included and presence of non-normally distributed variables, we used
non-parametric statistics for the analysis of autospectral differences. For the SESP muscles in patients,
and for all muscles in healthy controls, the results of the left and right muscles were first averaged.
A Mann–Whitney U test was used to compare the 8–14 Hz AUC’s and the CDF10 values between the
different muscles. To compare the AUC’s and CDF10 values between different measurements within
subjects, the Wilcoxon signed rank test was used. Due to the exploratory nature of this study, we made
no statistical corrections for multiple testing. To investigate the influence of age and gender, all subjects
were grouped together, and the mean 8–14 Hz AUC’s and CDF10 values of all muscles were calculated
for each subject. The influence of age was investigated using the Spearman rank correlation test, and
the influence of gender was investigated using the Mann–Whitney U test. The independent samples
t-test was used to compare the maximal produced force and torque during the MVC tasks between the
subjects. All statistical analyses were performed using SPSS 22 (IBM, Armonk, New York, USA).
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/9/9/256/s1,
Table S1: Muscles treated with BoNT.
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